The U.S. Food and Drug Administration announced Wednesday that it has approved Rasonque, a new oral medication for adults battling advanced pancreatic cancer. The pill, manufactured by Revolution Medicines in California, is taken once daily and targets multiple forms of the RAS protein that fuels tumor growth.
Why the approval matters
Pancreatic adenocarcinoma remains one of the deadliest cancers in the United States, accounting for up to 95% of roughly 67,000 new cases each year. Although it represents only about 3.2% of all cancer diagnoses, it causes a disproportionate share of cancer deaths because it is often detected late and spreads quickly.
Acting FDA Commissioner Kyle Diamantas called the decision “a critical new option for patients facing an extraordinarily difficult and historically hard‑to‑treat cancer.” He praised the agency’s scientists for their fast, thorough review and said the approval reflects the FDA’s fundamental duty to deliver more cures and meaningful treatments as quickly as possible.
Trial results show dramatic improvement
The approval follows a randomized, open‑label trial involving 500 patients with pre‑treated metastatic disease. Participants who received Rasonque achieved a median overall survival of 13.2 months, nearly double the 6.7‑month median seen in the standard chemotherapy control group.
“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.
Regulatory pathways that sped the process
Regulators accelerated Rasonque’s path to market by granting it priority review, orphan‑drug status, and a breakthrough‑therapy designation. The filing also benefited from the FDA commissioner’s National Priority Voucher pilot program, which is designed to speed access to critical public‑health treatments.
Earlier, in May, the agency issued a “safe to proceed” letter that opened an expanded‑access protocol, allowing patients to receive the drug before final approval.
Safety profile
Common adverse events reported in the trial included rash, diarrhea, mouth sores (stomatitis), nausea, fatigue, vomiting, abdominal pain, fluid retention (edema), reduced appetite, and bleeding (hemorrhage). These side effects are being closely monitored as the medication becomes more widely available.
Hope for patients and families
Anna Berkenblit, M.D., chief scientific and medical officer of the Pancreatic Cancer Action Network, called the approval “the most significant advance we have seen in the fight against pancreatic cancer.” She added that the new therapy could give patients more time with loved ones, improve quality of life, and inspire optimism for future research breakthroughs.
Rasonque’s approval marks a notable step forward in addressing a disease that has long eluded effective treatment, offering renewed hope to patients, families, and the broader medical community.
Original reporting: Fox News (HLL/CB) — read the source article.
